tbuckley/cabot-search huggingface dataset:
Great Britain Rowing Team Guideline for diagnosis and management of rib stress injury: Part 1
Authors: Guy Evans, Ann Redgrave
Journal: British Journal of Sports Medicine (2015)

Rib stress injury (RSI) is the development of pain due to bone oedema caused by overload along the rib shaft and is commonly seen in rowers. Often clinicians who manage this injury are experienced with the condition at the elite level. There may, however, be a lack of confidence in diagnosing and managing this condition by clinicians who are not regularly exposed to this injury. As a result, an evidence-based guideline has been developed to aid diagnosis and management of RSI.A detailed literature search was conducted reviewing the diagnosis and management of RSI. Detailed discussions were held by the Great Britain Rowing Medical Team to identify key issues in diagnosis and management of RSI. An up-to-date, evidence-based approach to managing RSI was created using both expert knowledge and current literature to formulate a functional guideline outlining best practice in management of RSI in rowers.A clinical guideline has been created incorporating 5 key areas: diagnosis, severity grading, investigation, management and associated risk factors for RSI. Important indicators for each key area are incorporated within the guideline using relevant literature where possible alongside expert opinion. The guideline has deliberately been kept concise and tailored for use in the clinical setting.A new clinical guideline for management of RSIs has been developed to facilitate clinicians in identifying RSI, aiding accurate diagnosis and providing effective management. This guideline is to be disseminated to clinicians, rowing coaches and clubs throughout the UK.
Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx.
Authors: I F Tannock, B J Cummings
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.2.343 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1732435 Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx. I F TannockxI F TannockSearch for articles by this author , B J CummingsxB J CummingsSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.2.343 First Page PDF © 1992 by American Society of Clinical Oncology
Evidence of a sub-clinical lymphoproliferative disease in patients with ‘idiopathic‘ autoimmune hemolytic anemia
Authors: F. R. Mauro, S. Coluzzi, I. Del Giudice, D. Armiento, M. S. De Propris, I. Della Starza, M. C. De Nicolo', A. Guarini, G. Girelli, R. Foa'
Journal: Journal of Clinical Oncology (2008)

7074 Background: Idiopathic autoimmune hemolytic anemia (AHA), which accounts for about half of cases, is diagnosed in the absence of a concomitant disease. A lymphoproliferative disease is frequently associated or can follow AHA. The aim of this study was to better define the clinical features of 50 cases defined as idiopathic AHA. Methods: Before starting steroid treatment, the following examinations were performed: immunohematologic study; total body CT scan or a chest XR with abdomen ultrasound; HBV and HCV serology; autoantibody screening (anti-nucleous; anti-cardiolipin; anti-gastric parietal cell; anti-beta 2-glycoprotein-I); peripheral blood (PB) immunophenotype. Results: The median age of the 50 patients was 66 years (range: 20–84), 32 patients were females. The immunohematologic study revealed an anti-erythrocyte auto-antibody in all cases (IgG: 27; IgM:15; IgG + IgM: 7; IgA:1). An idiopathic AHA was confirmed in 26 cases (52%), while in 24 (48%) a concurrent disease was diagnosed (tumor: 4; HCV hepatitis: 2; autoimmune disease: 2). In 16 cases (32 %), all with a normal lymphocyte count, the PB immunophenotype revealed the presence of a small B-lymphocyte clone with a CD5+/CD19+, CD23+ phenotype in 3 cases and a CD5+/CD19+, CD23- or CD5-/CD19+, CD23- phenotype in 13. The median number of clonal B lymphocytes in the PB was 0.5 x 109/L (range: 0.03–1.9 x 109/L). Clonality was confirmed by PCR. The same clonal population was detected in the bone marrow aspirate. No other signs ascribable to a lymphoproliferative disease were detected, except for a patient with an enlarged abdominal lymph node. Conclusions: Our findings indicate that about one third of newly diagnosed patients with otherwise defined “idiopathic” AHA show a underlined sub clinical B-lymphocyte clone which may play a role both in the pathogenesis of the autoimmune disorder and in the subsequent occurrence of a lymphoproliferative disease. The detection of such clones should be considered in the diagnostic work-out of patients with AHA. No significant financial relationships to disclose.
춘계학술대회 발표 : 포스터전시 ; 면역 억제 치료가 필요한 자가 면역성 간염 환자군의 임상적 특징
Authors: 최효선, 김홍주, 박정호, 박동일, 조용균, 손정일, 전우규, 김병익
Journal: Clinical and Molecular Hepatology (2006)
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response
Authors: Virginia Norris, Jane Bentley, Sandra Kent, Malcolm Boyce, Zuzana Diamant, Dave Singh, Brian O'Connor
Journal: European Respiratory Journal (2011)

Background: GSK2190915 is a potent 5-lipoxygenase activating protein inhibitor, thereby inhibiting the synthesis of leukotrienes and 5-oxo-ETE.

Objective: To assess the effect of GSK2190915 on the allergen-induced asthmatic response.

Methods: 19 eligible patients with mild asthma were enrolled and completed this 4- centre, double-blind, 2-way crossover study. They took 100 mg GSK2190915 and placebo orally once daily for 5 days, in randomised order. On Day 3 they had an inhaled allergen challenge and on Days 4 and 6 they had induced sputum collection.

Results: GSK2190915 attenuated the early (0-2 hours) and late (4-10 hours) asthmatic response to inhaled allergen compared to placebo. Following GSK2190915, the mean% attenuation of the placebo response to inhaled allergen for the minimum and weighted mean FEV1(0-2 hours) was 33.3% and 62.6%, respectively, and the mean% attenuation of the placebo response to inhaled allergen for the minimum and weighted mean FEV1(4-10 hours) was 15.8% and 22.7%, respectively. There was a significant attenuation of the allergen induced increase in sputum percent eosinophil count on Day 4 following GSK2190915 compared to placebo; the treatment difference (95% CI) was -9.95% (-18.13, -1.77). There was a >90% reduction in sputum LTB4 on Days 4 and 6 following treatment with GSK2190915 compared to placebo. Median sputum LTB4 (pg/mL) was 524 and 837 on Days 4 and 6 following placebo, and 31 and 18 on Days 4 and 6 following GSK2190915. Safety and tolerability were good.

Conclusion: GSK2190915 shows potential as a treatment for asthma.

ClinicalTrials.gov identifier [NCT00748306][1]

 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00748306&atom=%2Ferj%2F38%2FSuppl_55%2F3424.atom
THE GOLDEN GATE OF MEDICINE
Authors: A GREGG
Journal: Annals of Internal Medicine (1949)

Article1 April 1949THE GOLDEN GATE OF MEDICINEALAN GREGG, M.D.ALAN GREGG, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-30-4-810 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMay I begin with the bold hope that the almost effortless mastery of time and space which has brought you here has not imposed sophistication as the price of comfortable travel, nor robbed you of a pilgrim's vivid sensitiveness to stark and simple things. Unless, for a moment at least, you can give yourself to the realization of what this city of San Francisco has been and will always be, you will miss the significance as well as the fun of these meetings. That is why I hope you will abandon yourselves to the simplest things, dispense with all your... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ALAN GREGG, M.D.Affiliations: New York, N. Y.*Convocation address at the Twenty-ninth Annual Session of the American College of Physicians, San Francisco, California, April 21, 1948. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMeasles control: a best-practice challenge in public healthImmunization on Public TrialGuilds, Boards, and Hobgoblins 1 April 1949Volume 30, Issue 4Page: 810-822 ePublished: 1 December 2008 Issue Published: 1 April 1949 PDF downloadLoading ...
Matrix Glycoprotein SC1/ECM2 Augments B Lymphopoiesis
Authors: Kenji Oritani, Yuzuru Kanakura, Keisuke Aoyama, Takafumi Yokota, Neal G. Copeland, Debra J. Gilbert, Nancy A. Jenkins, Yoshiaki Tomiyama, Yuji Matsuzawa, Paul W. Kincade
Journal: Blood (1997)
Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer
Authors: S. Cho, S. Lee, J. Hwang, W. Bae, H. Shim, C. Park, M. Park, I. Chung
Journal: Journal of Clinical Oncology (2009)

4551 Background: S-1 is a fourth-generation oral fluoropyrimidine that was developed to mimic protracted continuous infusion of 5-fluorouracil (5-FU). In previous study, S-1 demonstrated promising activity which is comparable to combination chemotherapy in advanced gastric cancer. This phase II study evaluated the efficacy and safety of S-1 salvage chemotherapy, in patients with taxane and cisplatin refractory gastric cancer. The primary end point was progression free survival and secondary end points were overall survival, safety and clinical benefit. Methods: Patients were eligible if they had histologically documented gastric adenocarcinoma previously treated with taxane (docetaxel or paclitaxel) and cisplatin; age≥18; Eastern Clinical Oncology Group (ECOG) performance status of 2 or less; adequate organ function; no evidence of gastrointestinal obstruction or passage disturbance. S-1 treatment was performed according to BSA as followed; &lt; BSA 1.25, 80 mg/day, 1.25 ≤ BSA &lt; 1.5, 100 mg/day; BSA ≥ 1.5, 120 mg/day. Every dosage was delivered divided two times and administered for 4 weeks followed by 2 weeks of resting period. Treatment continued until progression of disease or life-threatening adverse events were occurred. Results: Fifty-four patients were enrolled in this study and of the patients, forty-eight patients were evaluable. A total 194 chemotherapy cycles were administered and median number of cycles was three. Four (8.3%) patients had a partial response and 18 (37.5%) patients had stable disease. The median progression free survival and overall survival were 3.8 and 10.2 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 6 patients (12.5%) and there was no febrile neutropenia. Most of nonhematologic toxicities were diarrhea, asthenia, and mucositis, and there was no grade 3 or grade 4 except two patients, who developed grade 3 anorexia and diarrhea, respectively. The clinical benefit response was observed in 16 patients (33.3%). Conclusions: This results showed that S-1 monotherapy was active and safe salvage chemotherapy in patients with advanced gastric cancer previously treated with taxane and cisplatin. No significant financial relationships to disclose.
Effect of sunitinib on TRAIL-induced apoptosis in preclinical colon cancer models
Authors: D. Mahalingam, E. Medina, R. T. Swords, K. R. Kelly, J. S. Carew, C. H. Robbert, E. Szegezdi, G. J. Francis, S. de Jong, S. T. Nawrocki
Journal: Journal of Clinical Oncology (2009)

e14633 Background: Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis, however not all cancers respond to TRAIL, which may be due to activation of survival signals. Sunitinib is a potent inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). These receptors and their signaling cascades promote cell survival and drug resistance. Inhibition of these pathways with sunitinib may augment TRAIL-mediated apoptosis. Aims: 1) Determine sensitivity of colon cancer cell lines to the combination of TRAIL and sunitinib, 2) identify mechanism by which sunitinib enhances TRAIL-mediated apoptosis, and 3) investigate the anticancer activity of this drug combination in xenograft models. Methods &amp; Results: Sunitinib enhanced the anticancer activity of TRAIL in HCT116 and HCT15 colon cancer cell lines, with increased caspase cleavage and DNA fragmentation using western blot analysis and propidium iodide staining, respectively. Overexpression of Bcl-2 in HCT116 cells reduced TRAIL+sunitinib-mediated apoptosis, suggesting that sunitinib enhances TRAIL-induced apoptosis via activation of the mitochondrial apoptotic pathway. Sunitinib enhanced TRAIL-induced JNK activation, which may play a role in TRAIL+sunitinib-mediated apoptosis. Xenograft models of HCT116 and HCT15 were established in nude mice and treated with TRAIL, sunitinib, or the combination. The TRAIL+sunitinib combination significantly reduced tumor burden in both xenograft models compared to either treatment alone. The reduction in tumor volume correlated with increased apoptosis and decreased tumor proliferation and angiogenesis as determined by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and immunohistochemistry for Proliferating Cell Nuclear Antigen and VEGF. Conclusion: These results are the first to demonstrate that simultaneous treatment with TRAIL and sunitinib reduced cell viability, induced apoptosis, inhibited tumor proliferation and angiogenesis in both in vitro and in vivo models of colon cancer, and warrants further investigation. No significant financial relationships to disclose.
Time to bin the term ‘overuse’ injury: is ‘training load error’ a more accurate term?
Authors: M K Drew, C Purdam
Journal: British Journal of Sports Medicine (2016)

We read the recent systematic review on the prevalence, incidence and risk factors for overuse injuries of the wrist in young athletes and agree with the conclusion that age and early specialisation (early training commencement) are risk factors for injury.1 The study highlighted training intensity as a risk factor for overuse injuries. Given changes in training loads precede the onset of injury in cricket,2 football (soccer)3 and Australian football,4 we consider that overuse injuries can be considered errors in training load prescription and labelled as such. Care should also be taken with broadly labelling training intensity as a risk factor as moderate training loads are protective against injury Gabbett's ‘training injury prevention paradox’.5 ,6 High training loads may predispose to …
The Russian influenza in Sweden in 1889-90: an example of Geographic Information System analysis
Authors: L Skog, H Hauska, A Linde
Journal: Eurosurveillance (2008)

Using data from a study of the 1889-90 Russian flu in Sweden, this article describes how the application of Geographic Information System (GIS) may improve analyses and presentation of surveillance data. In 1890, immediately after the outbreak, all Swedish doctors were asked to provide information about the start and the peak of the epidemic, and the total number of cases in their region and to fill in a questionnaire on the number, sex and age of infected persons in the households they visited. General answers on the epidemic were received from 398 physicians and data on individual patients were available for more than 32,600 persons. These historic data were reanalysed with the use of GIS, in map documents and in animated video sequences, to depict the onset, the intensity and the spread of the disease over time. A stack diagram with the observations grouped into one week intervals was produced to depict the spread in one figure only. To better understand how the influenza was disseminated, Thiessen polygons were created around 70 places reported on by the doctors. Having prepared GIS layers of the population (divided into parishes), estimations could be made for all the Swedish parishes on the number of infected persons for each of the 15 weeks studied. The described models may be useful in current epidemiological investigations, as well.
A strategy for clinical guidance using PD biomarkers revealed from human primary (HuPrime) tumors transplanted in nude mice
Authors: T. Chen, C. Liu, X. Song, L. Zhang, Y. Liu, J. Wery, Y. Chen
Journal: Journal of Clinical Oncology (2009)

e14612 Background: Most anticancer drug candidates, currently in clinical trials, have clear targets in molecular and cellular systems. However, such molecular targets are not always affected (or not correlated with efficacious endpoints) when the candidate is evaluated in a clinical setting. There is an urgent need to develop better biological tools and models to ease the transition between in vitro and in vivo, and between preclinical and clinical settings. Activation of tyrosine kinases in tumor cells has been recognized as key driving force in malignancy; therefore inhibitors of tyrosine kinases (TKI) have often shown efficacy in preclinical in vivo models and beneficial responses in clinical trials. An increasing number of TKI has been approved as anticancer drugs in selected cancer types. Methods: We have developed a unique platform combining our novel HuPrime™ xenograft models with our PD biomarker technologies. This platform is used to better understand the efficacy of novel drug candidates and generate information critical to maximize the chance of a successful clinical development. To illustrate the usefulness of our platform, we have applied it to understand the pharmacodynamic changes (at the molecular level) which are associated with the activity of sunitinib and sorafenib in our sensitive esophageal HuPrime models. Tumor tissues from sensitive esophageal HuPrime models treated with single dose of the respective drugs (and a vehicle control) have been collected at time-points 4, 8, 16, and 24 hour. Results: We have successfully applied immunohistochemistry (IHC) assays on many molecules covering most pathways including proliferation, apoptotic, necrotic, and cell cycle regulation, G2M phase arrest, DNA damage response, etc. Additional markers including angiogenesis can also be included for certain therapeutic compounds. These tissues have been analyzed with our platform and we have uncovered key molecular events which correlate with the efficacy and potency of the drugs. Conclusions: The PD biomarkers validated in this approach have potential for clinical application and patient stratification. [Table: see text]
Arsenic and Respiratory Cancer in Humans: Follow-Up of Copper Smelter Employees in Montana
Authors: A Lee-Feldstein
Journal: JNCI Journal of the National Cancer Institute (1983)

As a follow-up to an earlier study concerned with the role of arsenic in human carcinogenesis, the mortality experience during 1938-77 of 8,045 white male smelter employees in Montana exposed to arsenic trioxide was compared to that of the white male population of the same region. The excess mortality among smelter employees was due largely to respiratory cancer and diseases of the heart. Respiratory cancer mortality was analyzed with reference to period of first employment, length of employment, and degree of exposure to arsenic trioxide and sulfur dioxide. The excess in respiratory cancer was seven to eight times that expected among men first employed prior to 1925 who were heavily or moderately exposed to arsenic trioxide; it was more than four times that expected among men heavily exposed and first employed in 1925-47, and it decreased in direct proportion to degree of arsenic trioxide exposure. Inhaled arsenic trioxide was strongly implicated as the primary agent associated with the excess respiratory cancer, with sulfur dioxide perhaps enhancing the effect.
Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts)
Authors: G. Masi, G. Allegrini, L. Marcucci, S. Cupini, I. Brunetti, E. Fontana, S. Ricci, E. Cerri, C. Barbara, A. Falcone
Journal: Journal of Clinical Oncology (2004)

3690 Background: We conducted a phase I-II study with first line FOLFOXIRI (irinotecan 125–175 mg/sqm on day (d) 1, oxaliplatin 100 mg/sqm d1, LV 200 mg/sqm d1, 5-FU 3800 mg/sqm 48-h IV chronomodulated continuous infusion starting on d1, repeated every 2 weeks) and a phase II study with first line simplified FOLFOXIRI (irinotecan 165 mg/sqm d1, oxaliplatin 85 mg/sqm d1, LV 200 mg/sqm d1, 5-FU 3200 mg/sqm 48-h flat continuous infusion starting on d1, repeated every 2 weeks) respectively in 42 and 32 MCRC pts. Overall response rate, median progression free (PFS) and overall survival (OS) were 71% and 72%, 10.4 months (mos) and 10.8 mos, 26.5 mos and 28.4 mos respectively. A possible concern about the use of all three main active agents up-front is the possibility that this might limit, after progression, disease control with second line treatments. Methods: Among the 70 pts so far progressed 53 (76%) have received second line chemotherapy (22: FOLFIRI, 16: FOLFOXIRI, 5: 5-FU protracted infusion, 3: FOLFOX, 3: 5-FU+MMC, 2: CPT-11, 1: CPT-11+LOHP, 1: raltitrexed). Seventeen pts (24%) did not receive second line treatments: 10 because of deterioration of performance status (PS), 4 because of patient refusal and 3 because of death. Patients characteristics at the time of second-line treatment were: M/F 35/18 pts, median age 64 yrs (range 44–75), ECOG PS ≥ 1 21 (40%) pts, multiple sites of disease 33 (47%) pts. Results: A median of 4.2 mos of second-line chemotherapy per patient were administered (range 1–8). Overall response rate (51 out of 53 evaluable pts) was 31% (2CR+14PR, 95%CI=19–46%), stable disease were 19 (38%) and 16 pts (31%) progressed. Median duration of response was 7.7 mos. At a median follow up of 13.5 mos from the start of salvage chemotherapy median PFS and overall survival were respectively 6.7 and 15.2 mos. Conclusions: These results suggest that first line FOLFOXIRI does not impair the possibility to obtain objective responses and delay tumor progression with second line treatments containing the same agents used in first-line. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Pharma
One year follow-up result of autologous bone marrow cell infusion in patients with advanced Liver cirrhosis
Authors: Ja Kyung Kim, Young Nyun Park, Sjom Ok Ki, Sook In Chung, Hye Young Chang, Kyung Sik Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwan Sik Lee, Chae Yoon Chon, Byung Soo Moon, Kwang Hyub Ha
Journal: Clinical and Molecular Hepatology (2008)

Ja Kyung Kim, Young Nyun Park, Shin Ok Ki, Sook In Chung, Hye Young Chang, Kyung Sik Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwan Sik Lee, Chae Yoon Chon, Byung Soo Moon, Kwang-Hyub Han* Liver Cirrhosis Clinical Research Center, Department of Internal Medicine, Pathology, Diagnostic Radiology and Surgery, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea